PLA2G2F

Summary

PLA2G2F (phospholipase A2 group IIF, HGNC:30040) is a protein-coding gene on chromosome 1p36.12, encoding Group IIF secretory phospholipase A2 (Q9BZM2). Secretory calcium-dependent phospholipase A2 that primarily targets extracellular phospholipids.

Enables calcium-dependent phospholipase A2 activity. Involved in glycerophospholipid metabolic process. Predicted to be located in cytosol and extracellular region.

Source: NCBI Gene 64600 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 55 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_022819

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30040
Approved symbol	PLA2G2F
Name	phospholipase A2 group IIF
Location	1p36.12
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000158786
Ensembl biotype	protein_coding
OMIM	616793
Entrez	64600

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding, 1 retained_intron

ENST00000375102, ENST00000465062

RefSeq mRNA: 2 — MANE Select: NM_022819 NM_001360869, NM_022819

CCDS: CCDS204

Canonical transcript exons

ENST00000375102 — 5 exons

Exon	Start	End
ENSE00000908635	20143446	20143590
ENSE00000908636	20144580	20144689
ENSE00001465759	20148190	20150381
ENSE00001664731	20140166	20140218
ENSE00001958398	20139323	20139543

Expression profiles

Bgee: expression breadth broad, 42 present calls, max score 82.03.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1000 / max 28.1037, expressed in 33 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
1102	0.0926	33
1103	0.0074	3

Top tissues by expression

265 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skin of leg	UBERON:0001511	82.03	gold quality
skin of abdomen	UBERON:0001416	80.98	gold quality
zone of skin	UBERON:0000014	77.49	gold quality
urinary bladder	UBERON:0001255	64.11	gold quality
jejunal mucosa	UBERON:0000399	56.76	gold quality
pancreatic ductal cell	CL:0002079	56.69	silver quality
decidua	UBERON:0002450	56.55	gold quality
heart right ventricle	UBERON:0002080	55.77	gold quality
tibialis anterior	UBERON:0001385	54.79	silver quality
myocardium	UBERON:0002349	54.38	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	54.15	gold quality
cerebellar vermis	UBERON:0004720	53.34	gold quality
deltoid	UBERON:0001476	53.11	gold quality
gingival epithelium	UBERON:0001949	53.00	gold quality
hair follicle	UBERON:0002073	52.43	gold quality
gall bladder	UBERON:0002110	51.90	gold quality
jejunum	UBERON:0002115	51.87	gold quality
gingiva	UBERON:0001828	51.76	gold quality
upper leg skin	UBERON:0004262	51.05	gold quality
tibia	UBERON:0000979	50.87	gold quality
upper arm skin	UBERON:0004263	50.67	gold quality
epithelial cell of pancreas	CL:0000083	50.62	gold quality
ileal mucosa	UBERON:0000331	50.32	silver quality
tonsil	UBERON:0002372	50.13	gold quality
mammalian vulva	UBERON:0000997	49.37	gold quality
Brodmann (1909) area 46	UBERON:0006483	49.30	gold quality
blood vessel layer	UBERON:0004797	49.29	gold quality
mucosa of stomach	UBERON:0001199	49.22	gold quality
cervix squamous epithelium	UBERON:0006922	49.20	gold quality
quadriceps femoris	UBERON:0001377	49.17	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.02

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

80 targeting PLA2G2F, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-7112-5P	99.59	65.76	104
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-12123	99.52	71.79	2990

Literature-anchored findings (GeneRIF, showing 1)

• two of these isoforms, sPLA2 IIA and sPLA2 IIF, localize to the upper stratum granulosum and increase in response to experimental barrier perturbation. (PMID:24269828)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Pla2g2f	ENSMUSG00000028749
rattus_norvegicus	Pla2g2f	ENSRNOG00000016798
caenorhabditis_elegans		WBGENE00007419
caenorhabditis_elegans		WBGENE00015406

Paralogs (8): PLA2G10 (ENSG00000069764), PLA2G2D (ENSG00000117215), PLA2G5 (ENSG00000127472), PLA2G1B (ENSG00000170890), PLA2G2C (ENSG00000187980), PLA2G2A (ENSG00000188257), PLA2G2E (ENSG00000188784), OC90 (ENSG00000253117)

Protein

Protein identifiers

Group IIF secretory phospholipase A2 — Q9BZM2 (reviewed: Q9BZM2)

Alternative names: Phosphatidylcholine 2-acylhydrolase 2F

All UniProt accessions (1): Q9BZM2

UniProt curated annotations — full annotation on UniProt →

Function. Secretory calcium-dependent phospholipase A2 that primarily targets extracellular phospholipids. Hydrolyzes the ester bond of the fatty acyl group attached at the sn-2 position of phospholipids (phospholipase A2 activity), the catalytic efficiency decreasing in the following order: phosphatidylglycerols > phosphatidylethanolamines > phosphatidylcholines > phosphatidylserines. May play a role in lipid mediator production in inflammatory conditions, by providing arachidonic acid to downstream cyclooxygenases and lipoxygenases.

Subcellular location. Secreted. Cell membrane.

Tissue specificity. Expressed at high levels in placenta, testis, thymus and at lower levels in heart, kidney, liver and prostate. Highly expressed in rheumatoid arthritic tissues, including synovial lining cells in the intima, capillary endothelial cells and plasma cells.

Cofactor. Binds 1 Ca(2+) ion per subunit.

Miscellaneous. No signal peptide could be predicted in this isoform, challenging its subcellular location within the secretory pathway and hence the formation of disulfide bonds, which are required for its activity.

Similarity. Belongs to the phospholipase A2 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9BZM2-1	1	yes
Q9BZM2-2	2

RefSeq proteins (2): NP_001347798, NP_073730* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001211	PLA2	Family
IPR016090	PLA2-like_dom	Domain
IPR033113	PLA2_histidine	Active_site
IPR036444	PLipase_A2_dom_sf	Homologous_superfamily

Pfam: PF00068

Catalyzed reactions (Rhea), 6 shown:

• a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1-acyl-sn-glycero-3-phosphocholine + a fatty acid + H(+) (RHEA:15801)
• 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + (9Z)-octadecenoate + H(+) (RHEA:38779)
• 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphoethanolamine + (5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) (RHEA:40431)
• 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanolamine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphoethanolamine + (9Z,12Z)-octadecadienoate + H(+) (RHEA:40815)
• 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1’-sn-glycerol) + H2O = 1-hexadecanoyl-sn-glycero-3-phospho-(1’-sn-glycerol) + (9Z)-octadecenoate + H(+) (RHEA:40919)
• 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-L-serine + H2O = 1-hexadecanoyl-sn-glycero-3-phospho-L-serine + (9Z)-octadecenoate + H(+) (RHEA:41752)

UniProt features (22 total): disulfide bond 7, glycosylation site 4, binding site 4, active site 2, signal peptide 1, chain 1, region of interest 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BZM2-F1	89.46	0.76

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 67; 114

Ligand- & substrate-binding residues (4): 47; 49; 51; 68

Disulfide bonds (7): 46–138, 48–64, 63–120, 69–145, 70–113, 79–106, 98–111

Glycosylation sites (4): 102, 123, 144, 92

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-1482788	Acyl chain remodelling of PC
R-HSA-1482801	Acyl chain remodelling of PS
R-HSA-1482839	Acyl chain remodelling of PE
R-HSA-1482922	Acyl chain remodelling of PI
R-HSA-1482925	Acyl chain remodelling of PG
R-HSA-1483166	Synthesis of PA

MSigDB gene sets: 144 (showing top): GOBP_PHOSPHATIDYLSERINE_ACYL_CHAIN_REMODELING, GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, GOBP_PHOSPHATIDYLCHOLINE_METABOLIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_LEUKOCYTE_PROLIFERATION, KEGG_MAPK_SIGNALING_PATHWAY, IVANOVA_HEMATOPOIESIS_MATURE_CELL, GOBP_NEGATIVE_REGULATION_OF_CELL_CELL_ADHESION, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_LONG_CHAIN_FATTY_ACID_METABOLIC_PROCESS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_PHOSPHATIDYLGLYCEROL_METABOLIC_PROCESS, KEGG_FC_EPSILON_RI_SIGNALING_PATHWAY, GOBP_ORGANIC_ACID_TRANSPORT

GO Biological Process (14): lipid catabolic process (GO:0016042), arachidonate metabolic process (GO:0019369), phosphatidylglycerol acyl-chain remodeling (GO:0036148), phosphatidylserine acyl-chain remodeling (GO:0036150), phosphatidylcholine acyl-chain remodeling (GO:0036151), phosphatidylethanolamine acyl-chain remodeling (GO:0036152), negative regulation of T cell proliferation (GO:0042130), innate immune response (GO:0045087), phosphatidylcholine metabolic process (GO:0046470), phosphatidylglycerol metabolic process (GO:0046471), arachidonate secretion (GO:0050482), immune system process (GO:0002376), lipid metabolic process (GO:0006629), phospholipid metabolic process (GO:0006644)

GO Molecular Function (7): A2-type glycerophospholipase activity (GO:0004623), calcium ion binding (GO:0005509), phospholipid binding (GO:0005543), obsolete calcium-dependent phospholipase A2 activity (GO:0047498), protein binding (GO:0005515), hydrolase activity (GO:0016787), metal ion binding (GO:0046872)

GO Cellular Component (4): extracellular region (GO:0005576), cytosol (GO:0005829), plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Glycerophospholipid biosynthesis	6

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
lipid metabolic process	2
phosphatidylcholine metabolic process	2
glycerophospholipid metabolic process	2
catabolic process	1
long-chain fatty acid metabolic process	1
icosanoid metabolic process	1
unsaturated fatty acid metabolic process	1
olefinic compound metabolic process	1
phosphatidylglycerol metabolic process	1
phosphatidylserine metabolic process	1
T cell proliferation	1
regulation of T cell proliferation	1
negative regulation of lymphocyte proliferation	1
negative regulation of T cell activation	1
immune response	1
defense response to symbiont	1
icosanoid secretion	1
arachidonate transport	1
biological_process	1
primary metabolic process	1
organophosphate metabolic process	1
glycerophospholipase activity	1
carboxylic ester hydrolase activity	1
metal ion binding	1
lipid binding	1
binding	1
catalytic activity	1
cation binding	1
cytoplasm	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

392 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PLA2G2F	PLA2G3	Q9NZ20	700
PLA2G2F	PLA2G12B	Q9BX93	631
PLA2G2F	PLA2G12A	Q9BZM1	612
PLA2G2F	PLA2G4D	Q86XP0	500
PLA2G2F	PLA2G6	O60733	491
PLA2G2F	PLA2G4C	Q9UP65	451
PLA2G2F	PLA2G4A	P47712	445
PLA2G2F	PLA2G4F	Q68DD2	434
PLA2G2F	ENPP2	Q13822	432
PLA2G2F	PLA2G4B	P0C869	424
PLA2G2F	CYP2E1	P05181	419
PLA2G2F	PLA2G4E	Q3MJ16	407
PLA2G2F	PNPLA1	Q8N8W4	388
PLA2G2F	APOB	P04114	353
PLA2G2F	Q6ZTK2	Q6ZTK2	330

IntAct

2 interactions, top by confidence:

A	B	Type	Score
KLHL22	TRAV18	psi-mi:“MI:0914”(association)	0.350

BioGRID (4): PLA2G2F (Two-hybrid), PLA2G2F (Two-hybrid), MINOS1-NBL1 (Two-hybrid), PLA2G2F (Affinity Capture-MS)

ESM2 similar proteins: A0A411EZW9, A8E2V9, C1IC45, C1IC46, D0UGJ0, P00616, P00617, P00619, P00625, P06859, P0CAR9, P0CAS0, P0DUN0, P0DUN2, P17934, P20476, P23028, P58464, P59018, P70089, P70090, P84397, Q2HZ28, Q2PG81, Q2PG83, Q2PWA3, Q6H3D0, Q6H3D2, Q6H3D3, Q6H3D4, Q6H3D5, Q6H3D6, Q6H3D7, Q6YIJ3, Q6YNQ0, Q75S51, Q7T1R0, Q7ZTA7, Q800C2, Q800C3

Diamond homologs: A8CG78, A8CG82, A8CG84, A8CG87, A8CG89, B5U6Y4, B5U6Z2, B6CQR5, C0HJL8, C0HLF0, C0HMB2, C3W4R6, C9DPL5, F8QN52, F8QN54, G3DT18, O15496, O42187, O42188, P00606, P00622, P00626, P04057, P04417, P08872, P0CAR9, P0DJN7, P0DJP4, P0DMT1, P0DMT2, P0DMT3, P0DP54, P0DUP2, P11407, P14423, P14424, P14555, P17935, P20250, P20251

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

55 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	46
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

909 predictions. Top by Δscore:

Variant	Effect	Δscore
1:20139542:AGG:A	donor_loss	1.0000
1:20139544:G:GA	donor_loss	1.0000
1:20143444:A:AG	acceptor_gain	1.0000
1:20143445:G:GG	acceptor_gain	1.0000
1:20144687:GCA:G	donor_gain	1.0000
1:20144690:G:GG	donor_gain	1.0000
1:20148187:TAGGT:T	acceptor_loss	1.0000
1:20148189:G:A	acceptor_loss	1.0000
1:20148354:G:GT	donor_gain	1.0000
1:20142855:G:GT	donor_gain	0.9900
1:20143442:GCAGT:G	acceptor_loss	0.9900
1:20143445:G:A	acceptor_loss	0.9900
1:20143445:GT:G	acceptor_gain	0.9900
1:20143445:GTT:G	acceptor_gain	0.9900
1:20143445:GTTC:G	acceptor_gain	0.9900
1:20143445:GTTCT:G	acceptor_gain	0.9900
1:20143540:T:TA	donor_gain	0.9900
1:20143587:ACTGG:A	donor_loss	0.9900
1:20143588:CTGG:C	donor_loss	0.9900
1:20143589:TGGT:T	donor_loss	0.9900
1:20143591:G:GC	donor_loss	0.9900
1:20143591:G:GG	donor_gain	0.9900
1:20143592:T:G	donor_loss	0.9900
1:20143594:GGT:G	donor_loss	0.9900
1:20144686:TGCA:T	donor_gain	0.9900
1:20144687:GCAG:G	donor_gain	0.9900
1:20144688:CAG:C	donor_loss	0.9900
1:20144689:AG:A	donor_loss	0.9900
1:20144690:G:A	donor_loss	0.9900
1:20144691:TGAG:T	donor_loss	0.9900

AlphaMissense

1404 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000157925 (1:20141742 C>T), RS1000166259 (1:20144892 T>C), RS1000270590 (1:20146852 C>T), RS1000431844 (1:20150575 C>T), RS1000509031 (1:20141603 G>A,T), RS1000565457 (1:20145284 A>T), RS1000788812 (1:20140643 A>T), RS1000814520 (1:20150557 C>G,T), RS1001102926 (1:20150419 G>A), RS1001449622 (1:20142015 T>C), RS1001557203 (1:20145732 C>A,T), RS1001560884 (1:20141173 A>G), RS1001765336 (1:20145462 A>C), RS1001899347 (1:20140898 C>G), RS1002005029 (1:20145862 C>T)

Disease associations

OMIM: gene MIM:616793 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST008260_11	Group IIA secretory phospholipase A2 levels in individuals with elevated hsCRP	1.000000e-11
GCST008260_8	Group IIA secretory phospholipase A2 levels in individuals with elevated hsCRP	2.000000e-26

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL4278 (SINGLE PROTEIN), CHEMBL4524005 (PROTEIN FAMILY)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 272 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL148674	VARESPLADIB	2	272

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Phospholipase A₂

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
compound 12e [PMID: 18605714]	Inhibition	7.3	pIC50

ChEMBL bioactivities

12 potent at pChembl≥5 of 13 total, top 12 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.30	IC50	50	nM	CHEMBL515637
7.25	IC50	56	nM	CHEMBL4593409
7.05	IC50	90	nM	CHEMBL148649
7.05	IC50	90	nM	CHEMBL514705
6.94	IC50	114	nM	VARESPLADIB
6.89	IC50	130	nM	VARESPLADIB
6.88	IC50	131	nM	VARESPLADIB
6.54	IC50	290	nM	CHEMBL506485
6.26	IC50	550	nM	CHEMBL504813
6.26	IC50	550	nM	CHEMBL446349
6.01	IC50	970	nM	CHEMBL478820
5.96	IC50	1100	nM	CHEMBL514692

PubChem BioAssay actives

13 with measured affinity, of 42 total; 10 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2R)-3-[3-(5-benzyl-2-carbamoylphenyl)phenyl]-2-methylpropanoic acid	1631141: Inhibition of sPLA2 in human HepG2 cells	ic50	0.0140	uM
2-(1-benzyl-2-ethyl-3-oxamoylbenzo[g]indol-4-yl)oxyacetic acid	341247: Inhibition of human group2F phospholipase A2 fluorimetric assay	ic50	0.0500	uM
2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxypropanoic acid	341247: Inhibition of human group2F phospholipase A2 fluorimetric assay	ic50	0.0900	uM
2-[1-benzyl-2-(2-methylpropyl)-3-oxamoylbenzo[g]indol-4-yl]oxyacetic acid	341247: Inhibition of human group2F phospholipase A2 fluorimetric assay	ic50	0.0900	uM
2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetic acid	1614038: Inhibition of human recombinant sPLA2 assessed as reduction in 16:0 LPC formation after 30 mins by HPLC-MS analysis	ic50	0.1140	uM
2-[4-[2-(benzenesulfonamido)-2-oxoethoxy]-1-benzyl-2-(2-methylpropyl)benzo[g]indol-3-yl]-2-oxoacetamide	341247: Inhibition of human group2F phospholipase A2 fluorimetric assay	ic50	0.2900	uM
2-[1-benzyl-2-(2-methylpropyl)-3-oxamoylindol-4-yl]oxyacetic acid	341247: Inhibition of human group2F phospholipase A2 fluorimetric assay	ic50	0.5500	uM
2-[4-[2-(benzenesulfonamido)-2-oxoethoxy]-1-benzyl-2-ethylbenzo[g]indol-3-yl]-2-oxoacetamide	341247: Inhibition of human group2F phospholipase A2 fluorimetric assay	ic50	0.5500	uM
2-[2-(2-methylpropyl)-1-oxamoyl-3-[(2-phenylphenyl)methyl]indolizin-8-yl]oxyacetic acid	341247: Inhibition of human group2F phospholipase A2 fluorimetric assay	ic50	0.9700	uM
2-[4-[2-(benzenesulfonamido)-2-oxoethoxy]-1-benzyl-2-ethylindol-3-yl]-2-oxoacetamide	341247: Inhibition of human group2F phospholipase A2 fluorimetric assay	ic50	1.1000	uM

CTD chemical–gene interactions

10 total (human), top 10 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Resveratrol	affects cotreatment, decreases expression	2
benzo(e)pyrene	increases methylation	1
CGP 52608	affects binding, increases reaction	1
theaflavin-3,3’-digallate	affects expression	1
Benzo(a)pyrene	increases methylation	1
Copper	affects cotreatment, decreases expression	1
Methapyrilene	increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1

ChEMBL screening assays

17 unique, capped per target: 17 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3773530	Binding	Inhibition of human group 2F secreted phospholipase A2 assessed as remaining activity at 1000 nM by fluorescence assay	Development of a potent 2-oxoamide inhibitor of secreted phospholipase A2 guided by molecular docking calculations and molecular dynamics simulations. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.